News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Myriad Genetics, Inc. (MYGN)'s Lung Cancer Prognosis Test Shown to Significantly Predict Survival in Early Stage Lung Cancer Patients



6/4/2012 9:57:49 AM

SALT LAKE CITY, June 4, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a presentation entitled "Use of a Proliferation-Based mRNA Signature to Predict Outcome in Early-Stage Non-Small Cell Lung Adenocarcinoma," was presented on Sunday, June 3, 2012 at the American Society of Clinical Oncology® (ASCO) Annual Meeting in Chicago. The study demonstrates that the Company's lung cancer prognosis test significantly predicts cancer-specific death in early stage adenocarcinoma lung cancer patients.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES